COCH (Envoy Medical) Defensive Interval Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COCH Envoy Medical Inc COCH
6 GF Score
Price $0.71
GF Value $0.80
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Envoy Medical Defensive Interval Ratio?

COCH
6GF Score
Envoy Medical Inc COCH
Defensive Interval Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Envoy Medical (COCH) Overvalued in 2026?

Based on GuruFocus' analysis, Envoy Medical stock appears to be undervalued. The current stock price of $0.71 is trading 11.2% below its estimated GF Value™ of $0.80. GuruFocus considers Envoy Medical to be Modestly Undervalued.

Key valuation signals for COCH:

  • Defensive Interval Ratio:
  • GF Value™: $0.80 vs. price of $0.71 (11.2% below fair value)
  • GF Score™: 6/100 with 6 warning signs

No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Envoy Medical Business Description

Address 4875 White Bear Parkway, White Bear Lake, MN, USA, 55110
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
6GF Score

Get the complete analysis for COCH

Defensive Interval Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price
$0.80
GF Value